Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MET-097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Amneal and Metsera Announce Strategic Partnership for Obesity Medicines
Details : The collaboration aims to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including MET-097, a GLP-1 receptor agonists and amylin receptor agonists.
Brand Name : MET-097
Molecule Type : Peptide
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : MET-097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : ARCH Venture Partners
Deal Size : $290 million
Deal Type : Financing
Metsera Launches to Lead Next Generation Medicines for Obesity and Metabolic Diseases
Details : The proceeds will fund the development of oral and injectable incretin, non-incretin, and combination therapies, including injectable GLP-1 receptor agonists for obesity and metabolic diseases.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : ARCH Venture Partners
Deal Size : $290 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?